Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study

Michael O'Dwyer

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study

Michael O'Dwyer

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Abstract
Volume	114
Publication status	Published - 1 Nov 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{6fe714a9b0fc4b569fd0e111ac214103,

title = "Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study",

author = "Michael O'Dwyer",

year = "2009",

month = nov,

day = "1",

language = "English (Ireland)",

volume = "114",

type = "Other",

}